New hope for rare lymphoma: experimental drug targets tough cases
NCT ID NCT04414163
First seen Apr 24, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study tests an experimental drug called IMC-001 in 23 adults with a rare type of blood cancer (extranodal NK/T-cell lymphoma) that has returned or stopped responding to previous treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants receive the drug and are monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, South Korea
-
Chonnam National University Hwasun Hospital
Gwangju, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Ulsan University Hospital
Ulsan, South Korea
Conditions
Explore the condition pages connected to this study.